Gel encapsulation of glucose nanosensors for prolonged in vivo lifetime

Optical Nanosensors for in vivo Physiological Chloride Detection for Monitoring Cystic Fibrosis Treatment

Personalized approaches for continuous monitoring of chloride levels are potentially valuable for evaluating the efficacy of new treatments of genetic disorders such as cystic fibrosis. In this report, we validated optode-based nanosensors for real-time chloride monitoring in the interstitial fluid of living animals. These nanosensors take advantage of a ratiometric sensing scheme which demonstrates reversible and selective chloride detection in the physiological range. We further investigate how skin pigmentation affects the sensor performance during in vivo fluorescence imaging. We successfully monitored endogenous chloride changes using nanosensors during pharmacological treatment in a cystic fibrosis mouse model. We believe this platform is a valuable tool for chloride detection which could assess the efficacy of new treatments for cystic fibrosis.

Novel color standards for digital color analysis of optochemical sensor arrays

The indicator-based polymeric color standards for color referencing in digital color analysis (DCA) of optical chemical sensors (optodes) are proposed. In the novel standards, the colors referring to the actual absorption bands of the protonated and deprotonated forms of the indicator are mixed in constant proportions. The standards are based on the lipophilic pH-indicators: ETH5350 and ETH2439, commonly used in optodes, and the lipophilic electrolyte TBATBB. The dependence of the standard color on the TBATBB concentration in the optode is established and found to be linear. The standard colors remain unchanged upon varying the solution pH and the nature and the concentration of the electrolyte. Calibration curves of the indicator pH-optodes obtained in horse serum and referenced to the developed standards demonstrate lower error to span ratio, broader span and higher sensitivity as compared to the same data processed with the conventional gray standard. The colorimetric signal of the pH-optodes array measured in serum sample and referenced to the developed standards allowed accurate determination of the sample pH thus demonstrating practical prospects of the proposed color standards.

Role of Nanotechnology in Diabetic Management

BACKGROUND

Diabetes Mellitus (DM) has emerged as an epidemic that has affected millions of people worldwide in the last few decades. Nanotechnology is a discipline that is concerned with material characteristics at nanoscale and offers novel techniques for disease detection, management and prevention.

OBJECTIVE

Diabetes mellitus is an epidemic disease that has affected millions of people globally. Nanotechnology has greatly enhanced the health status by providing non-obtrusive techniques for the management and treatment of diabetic patients.

METHOD

In diabetes research, the nanotechnology has encouraged the advancement of novel glucose monitoring and several modalities for insulin delivery holding possibilities to enhance the personal satisfaction and life quality for diabetic patients.

RESULT

Nanoparticles hold a great potential in the areas of drug delivery and are explored as vehicles for orally administered insulin formulations. Glucose biosensors equipped with nanoscale materials such as Quantum Dots (QDs), Carbon Nanotubes (CNTs), Magnetic Nanoparticles (MNPs) etc. have shown greater sensitivity. Nanotechnology in diabetic research is heading towards the novel techniques which can provide continuous glucose monitoring offering accurate information and improving patient's compliance.

CONCLUSION

The present review addresses the different aspects of nanoparticles and recent patents related to diabetic management based on nanotechnology.

In Vivo Biosensing: Progress and Perspectives

In vivo biosensors are emerging as powerful tools in biomedical research and diagnostic medicine. Distinct from "labels" or "imaging", in vivo biosensors are designed for continuous and long-term monitoring of target analytes in real biological systems and should be selective, sensitive, reversible and biocompatible. Due to the challenges associated with meeting all of the analytical requirements, we found relatively few reports of research groups demonstrating devices that meet the strict definition in vivo. However, we identified several case studies and a range of emerging materials likely to lead to significant developments in the field.

Microfluidic Fabrication of Colloidal Nanomaterials-Encapsulated Microcapsules for Biomolecular Sensing

Implantable sensors that detect biomarkers in vivo are critical for early disease diagnostics. Although many colloidal nanomaterials have been developed into optical sensors to detect biomolecules in vitro, their application in vivo as implantable sensors is hindered by potential migration or clearance from the implantation site. One potential solution is incorporating colloidal nanosensors in hydrogel scaffold prior to implantation. However, direct contact between the nanosensors and hydrogel matrix has the potential to disrupt sensor performance. Here, we develop a hollow-microcapsule-based sensing platform that protects colloidal nanosensors from direct contact with hydrogel matrix. Using microfluidics, colloidal nanosensors were encapsulated in polyethylene glycol microcapsules with liquid cores. The microcapsules selectively trap the nanosensors within the core while allowing free diffusion of smaller molecules such as glucose and heparin. Glucose-responsive quantum dots or gold nanorods or heparin-responsive gold nanorods were each encapsulated. Microcapsules loaded with these sensors showed responsive optical signals in the presence of target biomolecules (glucose or heparin). Furthermore, these microcapsules can be immobilized into biocompatible hydrogel as implantable devices for biomolecular sensing. This technique offers new opportunities to extend the utility of colloidal nanosensors from solution-based detection to implantable device-based detection.

Alizarin Complexone Functionalized Mesoporous Silica Nanoparticles: A Smart System Integrating Glucose-Responsive Double-Drugs Release and Real-Time Monitoring Capabilities

The outstanding progress of nanoparticles-based delivery systems capable of releasing hypoglycemic drugs in response to glucose has dramatically changed the outlook of diabetes management. However, the developed glucose-responsive systems have not offered real-time monitoring capabilities for accurate quantifying hypoglycemic drugs released. In this study, we present a multifunctional delivery system that integrates both delivery and monitoring issues using glucose-triggered competitive binding scheme on alizarin complexone (ALC) functionalized mesoporous silica nanoparticles (MSN). In this system, ALC is modified on the surface of MSN as the signal reporter. Gluconated insulin (G-Ins) is then introduced onto MSN-ALC via benzene-1,4-diboronic acid (BA) mediated esterification reaction, where G-Ins not only blocks drugs inside the mesopores but also works as a hypoglycemic drug. In the absence of glucose, the sandwich-type boronate ester structure formed by BA binding to the diols of ALC and G-Ins remains intact, resulting in an fluorescence emission peak at 570 nm and blockage of pores. Following a competitive binding, the presence of glucose cause the dissociation of boronate ester between ALC and BA, which lead to the pores opening and disappearance of fluorescence. As proof of concept, rosiglitazone maleate (RSM), an insulin-sensitizing agent, was doped into the MSN to form a multifunctional MSN (RSM@MSN-ALC-BA-Ins), integrating with double-drugs loading, glucose-responsive performance, and real-time monitoring capability. It has been demonstrated that the glucose-responsive release behaviors of insulin and RSM in buffer or in human serum can be quantified in real-time through evaluating the changes of fluorescence signal. We believe that this developed multifunctional system can shed light on the invention of a new generation of smart nanoformulations for optical diagnosis, individualized treatment, and noninvasive monitoring of diabetes management.

Glucose-sensitive nanofiber scaffolds with an improved sensing design for physiological conditions

Continuous physiological monitoring of electrolytes and small molecules such as glucose, creatinine, and urea is currently unavailable but achieving such a capability would be a major milestone for personalized medicine. Optode-based nanosensors are an appealing analytical platform for designing in vivo monitoring systems. In addition to the necessary analytical performance, such nanosensors must also be biocompatible and remain immobile at the implantation site. Blood glucose in particular remains a difficult but high-value analyte to monitor continuously. Previously, we developed glucose-sensitive nanosensors that measure glucose by a competitive binding mechanism between glucose and a fluorescent dye to 4-carboxy-3-fluorophenyl boronic acid. To improve the sensitivity and residency time of our reported sensors, we present here a series of new derivatives of 4-carboxy-3-fluorophenyl boronic acid that we screened in a macrosensor format before translating into a nanofiber format with electrospinning. The lead candidate was then implanted subdermally and its residency time was compared to spherical nanosensor analogues. The nanofiber scaffolds were markedly more stable at the implantation site whereas spherical nanosensors diffused away within three hours. Based on the enhanced sensitivity of the new boronic acids and the residency time of nanofibers, this sensor configuration is an important step towards continuous monitoring of glucose and other analytes.

Implantable nanosensors: toward continuous physiologic monitoring

Continuous physiologic monitoring would add greatly to both home and clinical medical treatment for chronic conditions. Implantable nanosensors are a promising platform for designing continuous monitoring systems. This Feature reviews design considerations and current approaches toward such devices.